Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

We recently compiled a list of the 7 Best Stocks for Beginners with Little Money According to Analysts. In this article, we ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why ...